These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 22851270)

  • 1. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.
    Nakamura Y; Ratain MJ; Cox NJ; McLeod HL; Kroetz DL; Flockhart DA
    J Natl Cancer Inst; 2012 Aug; 104(16):1264; author reply 1266-8. PubMed ID: 22851270
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial.
    Stanton V
    J Natl Cancer Inst; 2012 Aug; 104(16):1265-6; author reply 1266-8. PubMed ID: 22851267
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
    Pharoah PD; Abraham J; Caldas C
    J Natl Cancer Inst; 2012 Aug; 104(16):1263-4; author reply 1266-8. PubMed ID: 22851268
    [No Abstract]   [Full Text] [Related]  

  • 4. CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned.
    Kelly CM; Pritchard KI
    J Natl Cancer Inst; 2012 Mar; 104(6):427-8. PubMed ID: 22395645
    [No Abstract]   [Full Text] [Related]  

  • 5. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
    Rae JM; Drury S; Hayes DF; Stearns V; Thibert JN; Haynes BP; Salter J; Sestak I; Cuzick J; Dowsett M;
    J Natl Cancer Inst; 2012 Mar; 104(6):452-60. PubMed ID: 22395643
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
    Regan MM; Leyland-Jones B; Bouzyk M; Pagani O; Tang W; Kammler R; Dell'orto P; Biasi MO; Thürlimann B; Lyng MB; Ditzel HJ; Neven P; Debled M; Maibach R; Price KN; Gelber RD; Coates AS; Goldhirsch A; Rae JM; Viale G;
    J Natl Cancer Inst; 2012 Mar; 104(6):441-51. PubMed ID: 22395644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
    Chlebowski RT; Col N
    J Natl Cancer Inst; 2008 Sep; 100(18):1331-2; author reply 132-3. PubMed ID: 18780870
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.
    Gurwitz D; Newman W
    J Natl Cancer Inst; 2008 Sep; 100(18):1331; author reply 1332-4. PubMed ID: 18780871
    [No Abstract]   [Full Text] [Related]  

  • 9. Endocrine treatment for ductal carcinoma in situ: balancing risks and benefits.
    Johnston SR
    Lancet; 2016 Feb; 387(10021):819-21. PubMed ID: 26686312
    [No Abstract]   [Full Text] [Related]  

  • 10. CYP2D6 genotype should not be used for deciding about tamoxifen therapy in postmenopausal breast cancer.
    Rae JM; Regan M; Leyland-Jones B; Hayes DF; Dowsett M
    J Clin Oncol; 2013 Jul; 31(21):2753-5. PubMed ID: 23775974
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of anastrozole on local recurrence in patients with favorable early breast cancer.
    Dizdar O; Harputluoglu H; Altundag K
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1651; author reply 1651. PubMed ID: 18035222
    [No Abstract]   [Full Text] [Related]  

  • 12. Anastrozole called breast cancer "lifesaver". Recipients showed a 40 percent decrease in relapse risk when switched to anastrazole after tamoxifen.
    Health News; 2005 Dec; 11(12):13-4. PubMed ID: 16416553
    [No Abstract]   [Full Text] [Related]  

  • 13. CYP2D6 genotype and tamoxifen response.
    Rae JM; Goetz MP; Hayes DF; Ingle JN; Li L; Storniolo AM; Stearns V; Flockhart DA
    Breast Cancer Res; 2005 Jul; 7(5):E6. PubMed ID: 16168100
    [No Abstract]   [Full Text] [Related]  

  • 14. Prioritizing pharmacogenetic research: a value of information analysis of CYP2D6 testing to guide breast cancer treatment.
    Woods B; Veenstra D; Hawkins N
    Value Health; 2011 Dec; 14(8):989-1001. PubMed ID: 22152167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.
    Lash TL; Cronin-Fenton D; Ahern TP; Rosenberg CL; Lunetta KL; Silliman RA; Garne JP; Sørensen HT; Hellberg Y; Christensen M; Pedersen L; Hamilton-Dutoit S
    J Natl Cancer Inst; 2011 Mar; 103(6):489-500. PubMed ID: 21325141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.
    Brauch H; Schroth W; Goetz MP; Mürdter TE; Winter S; Ingle JN; Schwab M; Eichelbaum M
    J Clin Oncol; 2013 Jan; 31(2):176-80. PubMed ID: 23091108
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.
    Gaston C; Kolesar J
    Clin Adv Hematol Oncol; 2008 Nov; 6(11):825-33. PubMed ID: 19194367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overcoming recurrence risk: extended adjuvant endocrine therapy.
    Cianfrocca M
    Clin Breast Cancer; 2008 Dec; 8(6):493-500. PubMed ID: 19073503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients.
    Nowell SA; Ahn J; Rae JM; Scheys JO; Trovato A; Sweeney C; MacLeod SL; Kadlubar FF; Ambrosone CB
    Breast Cancer Res Treat; 2005 Jun; 91(3):249-58. PubMed ID: 15952058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
    Goss PE
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S8-12. PubMed ID: 16730271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.